Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 9, 2016, Pages 1646-1653

  Nishida, Naoshi ^a   Yada, Norihisa ^a   Hagiwara, Satoru ^a   Sakurai, Toshiharu ^a   Kitano, Masayuki ^a   Kudo, Masatoshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

hepatocarcinogenesis; methylation; nonalcoholic steatohepatitis; oxidative stress; tumor suppressor gene

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; 8-OXO-7-HYDRODEOXYGUANOSINE; DEOXYGUANOSINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; APC GENE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOCHEMICAL EQUIPMENT; CDKN2A GENE; CHROMATIN IMMUNOPRECIPITATION; DNA DAMAGE; DNA METHYLATION; FEMALE; GENE EXPRESSION; GSTP1 GENE; HIC1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPID OXIDATION; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; RASSF1 GENE; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SOCS1 GENE; TUMOR SUPPRESSOR GENE; ANALOGS AND DERIVATIVES; BIOPSY; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; LIVER; LIVER CELL; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; PATHOLOGY;

ADULT; AGED; ALPHA-FETOPROTEINS; BIOPSY; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; DEOXYGUANOSINE; DNA DAMAGE; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION; GENES, TUMOR SUPPRESSOR; HEPATOCYTES; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATION-REDUCTION; PROMOTER REGIONS, GENETIC;

EID: 84988603381     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13318     Document Type: Article

References (21)

1. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005–23.
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980; 55: 434–8.
3. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999; 94: 2467–74.
4. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–21.
5. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J. Hepatol. 2002; 37: 56–62.
6. Tanaka S, Miyanishi K, Kobune M et al. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. J. Gastroenterol. 2013; 48: 1249–58.
7. O'Hagan HM, Wang W, Sen S et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell 2011; 20: 606–19.
8. Nishida N, Kudo M. Oxidative stress and epigenetic instability in human hepatocarcinogenesis. Dig. Dis. 2013; 31: 447–53.
9. Nishida N, Kudo M, Nagasaka T, Ikai I, Goel A. Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology 2012; 56: 994–1003.
10. Rowe JW, Wands JR, Mezey E et al. Familial hemochromatosis: characteristics of the precirrhotic stage in a large kindred. Medicine 1977; 56: 197–211.
11. Nishida N, Arizumi T, Takita M et al. Reactive oxygen species induce epigenetic instability through the formation of 8-hydroxydeoxyguanosine in human hepatocarcinogenesis. Dig. Dis. 2013; 31: 459–66.
12. Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR, Goel A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 2008; 47: 908–18.
13. Weisenberger DJ, Siegmund KD, Campan M et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 2006; 38: 787–93.
14. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. New Engl J. Med. 2013; 368: 1907–17.
15. Hashimoto E, Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic? Hepatol Res. 2012; 42: 1–14.
16. Borges LP, Borges VC, Moro AV, Nogueira CW, Rocha JB, Zeni G. Protective effect of diphenyl diselenide on acute liver damage induced by 2-nitropropane in rats. Toxicology 2005; 210: 1–8.
17. Asahina Y, Tsuchiya K, Nishimura T et al. alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 2013; 58: 1253–62.
18. Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317–25.
19. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, Network NCR. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810–20.
20. Caldwell S, Ikura Y, Dias D et al. Hepatocellular ballooning in NASH. J. Hepatol. 2010; 53: 719–23.
21. Murphy SK, Yang H, Moylan CA et al. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 1076–87.